Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer.

摘要

Taking into account the retrospective nature of the study which can influence the selection of patients, bevacizumab given in advanced lines after failure of conventional chemotherapy and antiepidermal growth factor receptor agents can result in high disease control rates in patients with mCRC.